medigraphic.com
ISSN 1527-3172 (Digital)

2011, Número 2

<< Anterior Siguiente >>

MEDICC Review 2011; 13 (2)


Drug-resistant HIV-1 in cuban children and their seropositive mothers

Pérez L, Correa C, Alemán CY, González I, Pérez J, Martínez PA, Álvarez A, Soto Y, Kourí V

Idioma: Ingles.
Referencias bibliográficas: 49
Paginas: 24-31
Archivo PDF: 268.37 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Clotet B, Menéndez-Arias L, Schapiro JM, Kuritzkes D, Burger D, Tural C, et al. Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis infected subjects. Barcelona: Fundació de Lluita contra la SIDA; 2008. 430 p.

  2. Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, et al. Universal Antiretroviral Therapy for Pregnant and Breast-Feeding HIV-1–Infected Women: Towards the Elimination of Mother-to-Child Transmission of HIV-1 in Resource-Limited Settings. Clin Infect Dis. 2009 Dec 15;49(12):1936–45.

  3. UNAIDS. AIDS epidemic update 2009 [Internet]. 2009 Nov [cited 2011 Mar 21]. Available from: http://data.unaids.org/pub/Report/2009/jc1700_ epi_update_2009_en.pdf

  4. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet. 1994 Dec 24–31;344(8939– 40):1771–2.

  5. Masquelier B, Chaix ML, Burgard M, Lechenadec J, Doussin A, Simon F, et al. Zidovudine Genotypic Resistance in HIV-1-Infected Newborns in the French Perinatal Cohort. J Acquir Immune Defi c Syndr. 2001 Jun 1;27(2):99–104.

  6. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, et al. Vertical Transmission of Multidrug-Resistant Human Immunodefi ciency Virus Type 1 (HIV-1) and Continued Evolution of Drug Resistance in an HIV-1-Infected Infant. J Infect Dis. 2001 Jun 1;183(11):1688–93.

  7. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL, et al. A Trial of Three Antiretroviral Regimens in HIV-1–Infected Children. N Engl J Med. 2004 Jun 10;350(24):2471–80.

  8. Nolan M, Fowler MG, Mofenson LM. Antiretroviral Prophylaxis of Perinatal HIV-1 Transmission and the Potential Impact of Antiretroviral Resistance. J Acquir Immune Defi c Syndr. 2002 Jun 1;30(2):216–29.

  9. Palumbo P, Holland B, Dobbs T, Pau CP, Luo CC, Abrams EJ, et al. Antiretroviral Resistance Mutations Among Pregnant Human Immunodefi ciency Virus Type 1-Infected Women and Their Newborns in the United States: Vertical Transmission and Clades. J Infect Dis. 2001 Nov 1;184(9):1120–6.

  10. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, et al. Perinatal acquisition of drugresistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology. 2009 Sep 19;6:85.

  11. De Luca A, Prosperi M, Bracciale L. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. Curr Opin HIV AIDS. 2010 Jan;5(1):27–37.

  12. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-infected women and prevention of perinatal HIV- 1 transmission. J Acquir Immune Defi c Syndr. 2002; 29:484–94.

  13. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dolfus C, et al. Motherto-child HIV transmission despite antirretroviral therapy in the ANRS French perinatal cohort. AIDS. 2008; 22:289–99.

  14. Pérez J, Pérez D, González I, Díaz Jidy M, Orta M, Aragonés C, et al. Approaches to the management of HIV/AIDS in Cuba [Internet]. Geneva: World Health Organization; 2004 [cited 2011 Mar 19]. 19 p. Available from: http://www.who.int/hiv/ pub/prev_care/en/cuba.pdf.

  15. Cancio I, Rocha N, Reymond V, Bermúdez R. Pautas para la atención integral al paciente con infección por VIH/sida en Cuba. Havana: Ministry of Public Health (CU); 2009. 62 p. Spanish.

  16. Kimura M. A simple method for estimating evolutionary rate of base substitution through comparative studies of nucleotide sequences. J Mol Evol. 1980 Dec;16(2):111–20.

  17. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform. 2004 Jun;5(2):150–63.

  18. Salminen MO, Carr JK, Burke DS, McCutchan FE. Identifi cation of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses. 1995 Nov;11(11):1423–5.

  19. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-Length Human Immunodefi ciency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination. J Virol. 1999 Jan;73(1):152–60.

  20. Hillis DM, Allard MW, Miyamoto MM. Analysis of DNA sequence data: phylogenetic inference. Methods Enzymol. 1993;224:456–87.

  21. HIV Drug Resistance Database [Internet]. Stanford: Stanford University. c1998-2011 [cited 2011 Mar 10]. Available from: http://hivdb.stanford. edu/.

  22. Geelen SP. [HIV infection in children and the prevention of mother-to-child transmission]. Ned Tijdschr Geneeskd. 2002 Jul 6;146(27):1261–4. Dutch.

  23. Ferreira FG, Pinto JA, Kakehasi FM, Cleto S, Tupinambás U, Aleixo AW, et al. Prevalence of Primary Drug Resistance-Associated Mutations Among HIV Type 1 Vertically Infected Children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses. 2010 Feb 15;26(2):229–32.

  24. Villahermosa ML, Thomson M, Vázquez de Parga E, Cuevas MT, Contreras G, Pérez-Alvarez L, et al. Improved Conditions for Extraction and Amplifi cation of Human Immunodefi ciency Virus Type 1 RNA From Plasma Samples With Low Viral Load. J Hum Virol. 2000 Jan–Feb;3(1):27–34.

  25. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, et al. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defi c Syndr. 2001 Nov 1;28(3):254–8.

  26. Muñoz Fernández MA. [Virological diagnosis of HIV infection in children]. Allergol Immunopathol (Madr). 1998 May–Jun;26(3):122–9. Spanish.

  27. Sire JM, Vray M, Merzouk M, Plantier JC, Pavie J, Maylin S, et al. Comparative RNA Quantifi cation of HIV-1 Group M and Non-M With the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real Time HIV-1 PCR assays. J Acquir Immune Defi c Syndr. 2011 Mar 1;56(3):239–43.

  28. Blanco M, Rolo F, Martínez N, Gessa A, Díaz H, Lubián AL. Aplicación del ensayo de movilidad del heterodúplex en los estudios de epidemiología molecular del VIH-1 en Cuba. Biotecnología Aplicada. 2001;18(3):149–53. Spanish.

  29. Cuevas MT, Ruibal I, Villahermosa ML, Díaz H, Delgado E, Parga EV, et al. High HIV-1 genetic diversity in Cuba. AIDS. 2002 Aug 16;16(12):1643–53.

  30. Pérez L, Thomson MM, Bleda MJ, Aragonés C, González Z, Pérez J, et al. HIV Type 1 Molecular Epidemiology in Cuba: High Genetic Diversity, Frequent Mosaicism, and Recent Expansion of BG Intersubtype Recombinant Forms. AIDS Res Hum Retroviruses. 2006 Aug;22(8):724–33.

  31. Hasegawa N, Sugiura W, Shibata J, Matsuda M, Ren F, Tanaka H. Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. BMC Bioinformatics. 2009 Oct 29;10:360.

  32. Buendia P, Narasimhan G. Sliding MinPD: building evolutionary networks of serial samples via an automated recombination detection approach. Bioinformatics. 2007 Nov 15;23(22):2993–3000.

  33. González Núñez I, Díaz Jidy M, Pérez Avila J. [Mother to child transmission of infantile HIV/ AIDS in Cuba]. Rev Cubana Med Trop. 2000 Sep–Dec;52(3):220–4. Spanish.

  34. González Núñez I, Díaz Jidy M, Pérez Ávila J, Mengana Gutiérrez HL. [Antiretroviral therapy in HIV/AIDS seropositive pregnant women in Cuba]. Rev Cubana Med Trop. 2004 JanApr;56(1):70–2. Spanish.

  35. Glikman D, Walsh L, Valkenburg J, Mangat PD, Marcinak JF. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications. Pediatrics. 2007 May;119(5):e1142–8.

  36. Mullen J, Leech S, O’Shea S, Chrystie IL, Du Mont G, Ball C, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002 Nov;68(3):299–304.

  37. Tsertsvadze T, Bolokadze N, Sharvadze L, Gabunia P, Dvali N. Antiretroviral treatment in Georgia. Georgian Med News. 2008 Dec;(165):10–6.

  38. Tornatore M, Gonçalves CV, Mendoza-Sassi RA, Silveira JM, D’Ávila NE, Maas CG, et al. HIV-1 vertical transmission in Rio Grande, Southern Brazil. Int J STD AIDS. 2010 May;21(5):351–5.

  39. Shafer RW. The challenge of antiretroviral drug resistance in HIV-1-infected children. J Pediatr (Rio J). 2009 Mar–Apr;85(2):91–4. English, Portuguese.

  40. Gupta RK, Gibb DM, Pillay D. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis. 2009 Jun;22(3):256–63.

  41. Adjé-Touré C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d’Ivoire. AIDS Res Hum Retroviruses. 2008 Jul;24(7):911–7.

  42. Zhang F, Haberer J, Wei H, Wang N, Chu A, Zhao Y, et al. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS. 2009 Jun;20(6):406–9.

  43. Vignoles M, Barboni G, Agosti MR, Quarleri J, Garcia MK, Ayala SG, et al. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. Antivir Ther. 2009;14(8):1175–81.

  44. Liu ZY, Wei HS, Zhao HX, Liu YN, Zhao Y, Han N, et al. [HIV-1 genotypic resistance profi les in children failing highly active antiretroviral therapy]. Zhonghua Yi Xue Za Zhi. 2007 Dec 11;87(46):3292–4. Chinese.

  45. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defi c Syndr. 2007 Oct 1;46(2):187–93.

  46. Machado DM, Fernandes SC, Succi RC, Freire WS, Pannuti CS, Gouveia AB, et al. Analysis of HIV-type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). Rev Inst Med Trop Sao Paulo. 2005 Jan–Feb;47(1):1–5.

  47. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S. HIV-1 drug resistance mutations in children who failed non nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):83–8.

  48. Simonetti SR, Schatzmayr HG, Simonetti JP. Human immunodefi ciency virus type 1: drug resistance in treated and untreated Brazilian children. Mem Inst Oswaldo Cruz. 2003 Sep;98(6):831–7.

  49. Mihailidis C, Dunn D, Pillay D, Pozniak A. Effect of isolated V118I mutation in reverse transcriptase on response to fi rst-line antiretroviral therapy. AIDS. 2008 Jan 30;22(3):427–30.




2020     |     www.medigraphic.com